Minocycline

Classification

• Minocycline is a semi‑synthetic, broad‑spectrum tetracycline antibiotic.

Chemical identity

• IUPAC name: (2S,4R,5S,7R)-4‑[[(2‑amino‑2‑oxoethyl)amino]methyl]‑5‑[(2‑hydroxy‑4‑methyl‑3‑oxo‑1‑pyrrolidinyl)methyl]‑7‑[(2‑dimethylamino)ethyl]‑2­-hydroxy‑6‑methoxy‑2‑pyridone.
• Molecular formula: C₂₃H₂₄N₂O₅·HCl (as the hydrochloride salt).
• Molecular weight: ≈ 495 g·mol⁻¹ (hydrochloride).

Mechanism of action

• Inhibits bacterial protein synthesis by binding reversibly to the 30S ribosomal subunit, preventing attachment of aminoacyl‑tRNA and thus blocking translation.
• Exhibits bacteriostatic activity against susceptible organisms; at higher concentrations it may be bactericidal.

Spectrum of activity

• Effective against many Gram‑positive and Gram‑negative bacteria, including Staphylococcus aureus (including some methicillin‑resistant strains), Streptococcus spp., Neisseria gonorrhoeae, Chlamydia trachomatis, Rickettsia spp., Mycoplasma spp., and certain anaerobes.

Approved clinical uses

• Acne vulgaris: oral therapy for moderate to severe inflammatory acne.
• Skin and soft‑tissue infections: as an alternative to other tetracyclines.
• Respiratory tract infections: e.g., community‑acquired pneumonia caused by susceptible organisms.
• Genitourinary infections: uncomplicated gonorrhea and chlamydial infections.
• Rickettsial diseases: such as Rocky Mountain spotted fever and typhus.
• Other: off‑label use in certain neuroinflammatory conditions (e.g., rheumatoid arthritis, multiple sclerosis) has been studied but remains investigational.

Pharmacokinetics

• Absorption: Oral bioavailability ≈ 90 %; food reduces absorption modestly.
• Distribution: Widely distributed; penetrates skin, lung, and cerebrospinal fluid. High lipid solubility leads to accumulation in tissues, including bone and the central nervous system.
• Metabolism: Primarily hepatic via oxidation and N‑demethylation.
• Elimination: Approximately 30–50 % renal excretion of unchanged drug; remainder excreted in bile and feces. Half‑life ≈ 11–22 hours, allowing twice‑daily dosing.

Dosage forms

• Oral tablets (commonly 50 mg, 100 mg).
• Oral capsules (100 mg).
• Intravenous formulation (100 mg vials) for severe infections.

Common dosing regimens

• Acne: 100 mg orally once daily (often with a loading dose).
• Acute bacterial infections: 100 mg orally twice daily; duration varies with infection type.
• Children (≥ 8 years): weight‑based dosing, generally 2–4 mg/kg/day divided every 12 hours.

Adverse effects

• Gastrointestinal: nausea, vomiting, dyspepsia, diarrhea.
• Dermatologic: photosensitivity, rash, hyperpigmentation (particularly of scar tissue and oral mucosa).
• Neurologic: dizziness, vertigo, vestibular disturbances.
• Hematologic: reversible, dose‑dependent neutropenia, thrombocytopenia.
• Hepatic: transient elevations of liver enzymes; rare cases of hepatotoxicity.
• Rare but serious: drug‑induced lupus‑like syndrome, autoimmune hepatitis, Stevens‑Johnson syndrome, toxic epidermal necrolysis, idiopathic intracranial hypertension.

Contraindications

• Known hypersensitivity to minocycline, other tetracyclines, or any component of the formulation.
• Pregnancy (Category D) and lactation: associated with fetal bone growth inhibition, teeth discoloration, and other adverse fetal outcomes.
• Children < 8 years of age: risk of permanent tooth discoloration and enamel hypoplasia.

Drug interactions

• Absorption: Antacids, calcium‑rich foods, iron supplements, and zinc can chelate minocycline, reducing its absorption; administration should be spaced ≥ 2 hours apart.
• Warfarin: potentiation of anticoagulant effect, necessitating INR monitoring.
• Cyclosporine: increased risk of nephrotoxicity.
• Oral contraceptives: possible reduction in contraceptive efficacy; alternative non‑hormonal methods recommended.

Pharmacogenomics

• Genetic polymorphisms affecting hepatic enzymes (e.g., CYP3A4) may influence metabolism, but clinically significant variability is not well‑established.

Regulatory status

• Approved by the U.S. Food and Drug Administration (FDA) and equivalent agencies worldwide for the indications listed above.
• Patent for minocycline expired; generic formulations are widely available.

References

• FDA prescribing information for Minocycline (various manufacturers).
• British National Formulary (BNF) – Minocycline entries.
• Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13th ed., 2023.

This summary reflects current knowledge up to the cutoff date of June 2024.